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Abstract
Background: Family with sequence similarity 3, member C (FAM3C) has been identified as a novel regulator in
epithelial-mesenchymal transition (EMT) and metastatic progression. However, the role of FAM3C in esophageal
squamous cell carcinoma (ESCC) remains unexplored. The purpose of present study is to illustrate the role of
FAM3C in predicting outcomes of patients with ESCC.
Methods: FAM3C expression was measured in ESCC tissues and the matched adjacent nontumorous tissues by
quantitative real-time RT-PCR and Western blot analysis. The relationship between FAM3C expression and prognosis of
ESCC patients was further evaluated by univariate and multivariate regression analyses. Univariate and multivariate
analyses of the prognostic factors were performed using Cox proportional hazards model.
Results: The FAM3C mRNA expression was remarkably upregulated in ESCC compared with their nontumor counterparts
(P < 0.001). In addition, high expression of FAM3C was significantly associated with pT stage (P = 0.014) , pN stage
(P = 0.026) and TNM stage (P = 0.003). Kaplan-Meier analysis showed that the 7-year overall survival rate in the
group with high expression of FAM3C was poorer than that in low expression group (32.0 versus 70.9 %; P < 0.001).
Univariate and multivariate analyses demonstrated that FAM3C was an independent risk factor for overall survival.
Moreover, Stratified analysis revealed that FAM3C expression could differentiate the prognosis of patients in early
clinical stage (TNM stage I-II).
Conclusions: FAM3C expression was dramatically increased in ESCC and might serve as a valuable prognostic indicator
for ESCC patients after surgery.
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Background
Esophageal cancer (EC) is one of the most common ma-
lignancies and ranked as the sixth leading cause of cancer-
related mortality worldwide [1, 2]. Esophageal squamous
cell carcinoma (ESCC), the most prevalent histological
subtype of EC, is characterized by its remarkable geo-
graphic distribution, and predominates in Northern Iran,
South Africa, and Northern China, especially in Henan
province [3, 4]. Despite the recent advances in diagnosis
and treatment, the prognosis of ESCC patients remains
dismal and the 5-year overall survival rate is ranging from
10 to 41 % [5–7]. ESCC has been viewed as a complex
and heterogeneous disease which is driven by a series of
genetic and epigenetic alterations. Therefore, it is impera-
tive to search for sensitive and specific biologic markers
for prevention, screening, diagnosis and development of
specific therapies.
To obtain a clear picture of genetic alterations occurring
in ESCC patients, our group performed high-throughput
transcriptome sequencing (RNA-Seq) on three matched
pairs of ESCC and the adjacent nontumorous tissues to
identify differentially expressed genes. Family with se-
quence similarity 3, member C (FAM3C), or interleukin-
like epithelial-mesenchymal transition inducer (ILEI)
brought up our attention due to its significantly upregu-
lated expression in ESCC specimens. It belongs to the
family with sequence similarity 3 (FAM3) superfamily and
encodes a secreted protein with a GG domain. There are
four members in this family, FAM3A, FAM3B, FAM3C,
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and FAM3D, each encoding a protein (224–235 amino
acids) with a hydrophobic leader sequence [8]. FAM3C
was initially identified as a candidate gene for autosomal
recessive non-syndromic hearing loss locus 17 (DFNB17)
[9]. Recent works have revealed that FAM3C was a novel
regulator of epithelial-mesenchymal transition (EMT) and
metastatic progression [10, 11]. In addition, overexpres-
sion of FAM3C was detected in pancreatic cancer and
colorectal cancer [12, 13], suggesting important roles of
FAM3C in the metastasis and progression of cancer. How-
ever, the expression pattern and clinical significance of
FAM3C in ESCC has not been explored.
Here we measured the expression level of FAM3C in
ESCC and matched adjacent nontumorous specimens,
and further explored its clinicopathological significance
and prognostic value in ESCC.
Methods
Patients and tissue samples
One hundred seven primary ESCC tumor and 40 paired
adjacent nontumorous tissue samples were collected im-
mediately after surgery resection at Sun Yat-sen Univer-
sity Cancer Center between March 2002 and October
2008. The inclusion criteria were as follows: (a) definitive
ESCC diagnosis by pathology based on WHO criteria;
(b) complete surgical resection, defined as complete
resection of all tumor nodules with the cut surface being
free of cancer by histologic examination; (c) no neoadju-
vant or adjuvant treatment before surgery; (d) complete
clinicopathologic and follow-up data. Ethical approval
for this study was granted by the Medical Ethics Com-
mittee of Sun Yat-sen University Cancer Center. All
patients signed informed consent. Tumor differentiation
(G1, well differentiated; G2, moderately differentiated; G3,
poorly differentiated), depth of tumor invasion (pT stage)
and lymph node metastasis (pN stage) were determined
by pathologic examination. Tumor staging was deter-
mined according to the seventh edition tumor-node-
metastasis (TNM) classification of the American Joint
Committee on Cancer [14].
Quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR)
All fresh tumorous and nontumorous tissue samples were
taken from regions which macroscopically judged to be
neoplastic and normal, respectively. Both of them were
immediately stored at dry ice after resection and then fro-
zen at −80 °C. Total RNA was extracted from clinical sam-
ples using TRIzol reagent (Invitrogen), and was reverse-
transcribed using an Advantage RT-for-PCR Kit (Clontech
Laboratories) according to the manufacturer’s instruc-
tions. qRT-PCR was performed to detect mRNA levels of
the corresponding glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), FAM3C, E-cadherin and vimentin using
a SYBR Green PCR Kit (Applied Biosystems) and
LightCycler480 384-well PCR system (Roche Diagnostics).
The GAPDH was used as an internal control for FAM3C,
E-cadherin and vimentin. Primers for FAM3C are 5′-
CCTTGGCAAATGGAAAAACAGG-3′ (forward) and 5′-
CCCAAATCAGCAATGAGCCG-3′ (reverse). Primers for
E-cadherin are 5′-TGAAGGTGACAGAGCCTCTGGAT-
3′ (forward) and 5′-TGGGTGAATTCGGGCTTGTT-3′
(reverse). Primers for vimentin are 5′-CCTTGAACGCAA
AGTGGAATC-3′ (forward) and 5′-GACATGCTGTTC
CTGAATCTGAG-3′ (reverse). Primers for GAPDH are
5′-ACTTCAACAGCGACACCCACTC-3′ (forward) and
5′-TACCAGGAAATGAGCTTGACAAAG-3′ (reverse).
The value of relative expression for each sample was aver-
aged and compared using the Ct method. ΔΔCt(sample) =
ΔCt(sample) - ΔCt(calibrator), ΔCt(sample) = Ct(sample)
of target gene - Ct(sample) of GAPDH; ΔCt(calibrator) =
Ct(calibrator) of target gene - Ct(calibrator) of GAPDH;
calibrator was defined as the pooled samples from 40 adja-
cent nontumorous tissues. The fold changes in mRNAs
were calculated by the equation 2–ΔΔCt.
Western blot analysis
Frozen tissue specimens were ground under liquid
nitrogen. Total protein was extracted with lysis buffer
for one hour on ice. Equal amounts of protein were sep-
arated by 15 % SDS-PAGE and electrophoretically trans-
ferred to polyvinylidene difluoride membranes (Roche)
using a mini trans-blot apparatus (Bio-Rad Laboratories).
Membranes were blocked with TBS-0.1 % Tween 20
containing 5 % nonfat dry milk for one hour at room
temperature and incubated with rabbit polyclonal anti-
body against FAM3C (1:1,000; Proteintech) or GAPDH
(1:1,000; Abgent) at 4 °C overnight. Membranes were then
washed three times with TBS-0.1 % Tween 20 and incu-
bated with horseradish peroxidase (HRP) –conjugated
goat anti-rabbit IgG antibody (Cell Signaling Technology)
at a 1:3,000 dilution for one hour at room temperature.
Blots were developed using a Luminata Crescendo
Western HRP substrate (Millipore). GAPDH was used
as a loading control.
Statistical analysis
All statistical analyses were performed using the Statis-
tical Package for the Social Sciences (SPSS) version 16.0
(SPSS Inc, Chicago, IL). Paired two-tailed student’s t test
was used to compare the expression of FAM3C in
primary ESCC tumors and their corresponding adjacent
nontumorous tissues. The correlation between FAM3C
expression and clinicopathological parameters was
assessed by chi-square test or Fisher’s exact test. Overall
survival (OS) was defined as the interval from curative
surgery to either the time of death from ESCC or last
follow up (30 June 2015). The prognostic value was
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calculated by the Kaplan-Meier analysis with log-rank
test. Univariate and multivariate survival analyses were
performed using the Cox proportional hazard model
with a forward stepwise procedure (the entry and re-
moval probabilities were 0.05 and 0.10, respectively). A
significant difference was considered statistically when
P value was < 0.05.
Results
Expression of FAM3C in ESCC
Our previous RNA-seq data showed that FAM3C was
overexpressed in all three tested ESCC tumor tissues com-
pared to corresponding nontumor tissues. The mRNA ex-
pression of FAM3C was initially tested in 40 pairs of
primary ESCC tumors and their normal counterparts by
qRT-PCR. Elevated expression of FAM3C (defined as > 2-
fold change) was detected in 28 of 40 (70.0 %) of ESCC
tissues compared with the matched nontumorous tissues
(Fig. 1a). The average level of FAM3C expression in tumor
specimens was dramatically higher than that in nontumor
specimens (5.72 versus 1.61, P < 0.001, paired Student’s
t test; Fig. 1a). To confirm our findings, Western blot
analysis of FAM3C expression was performed in the
paired ESCC and the nontumor specimens of 12 ran-
domly selected ESCCs from the 40 cases described
above. Consistently, the upregulation of FAM3C pro-
tein was observed in 8 of 12 ESCC tissues compared
with their matched nontumor specimens (Fig. 1b).
Correlation of FAM3C mRNA expression with EMT markers
To determine the correlation between the expression of
FAM3C and EMT, expression patterns of FAM3C and
EMT-associated markers, including E-cadherin and vimentin,
were assessed by qRT-PCR in 40 ESCC specimens described
Fig. 1 Upregulation of FAM3C in ESCC. a FAM3C mRNA expression in ESCC and matched adjacent nontumor specimens from 40 cases of ESCC
patients. The dot plots represent the FAM3C expression in tumor and nontumor samples from 40 ESCCs. **, P < 0.001, paired t-test. b Western blot
analysis of FAM3C expression levels in 12 paired ESCC and nontumor specimens. GAPDH was used as a loading control. N, nontumor tissue; T, tumor
tissue. c Analysis showing linear regressions and significant Pearson correlations of FAM3C with E-cadherin and FAM3C with vimentin in 40 ESCC samples
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above. Linear regression analyses showed that the expres-
sion of FAM3C was negatively correlated with E-cadherin
expression (R = −0.557, P < 0.001), but positively correlated
with vimentin expression (R = 0.582, P < 0.001; Fig. 1c).
Correlation of FAM3C mRNA expression with
clinicopathological variables
Subsequently, we examined the correlation between
the expression of FAM3C and the clinicopathological
features of ESCC. High level expression of FAM3C was
detected in 71/107 (66.4 %) of informative ESCC
tissues. The median fold change of FAM3C (2.28) in
ESCC tumor specimens was used as a cutoff value to
divide all 107 patients into two groups: high expression
group (n = 53) and low expression group (n = 54). As
showed in Table 1, high expression of FAM3C was
significantly associated with pT stage (P = 0.014), pN
stage (P = 0.026) and TNM stage (P = 0.003). No cor-
relation was observed between FAM3C expression and
other clinicopathological index.
FAM3C mRNA expression and patient outcomes
The association between FAM3C expression and progno-
sis of ESCC patients was investigated by Kaplan-Meier
analysis and log-rank test. As shown in Fig. 2a, ESCC
patients with high FAM3C expression had poorer OS than
those with low FAM3C expression. The 1, 3, and 7-year
OS rate in the high FAM3C expression group were 82.5,
42.9, and 32.0 %, respectively, compared with 88.7, 75.3,
and 70.9 %, respectively, in the low FAM3C expression
group (log-rank test, P < 0.001). In the univariate analysis,
the statistically significant predictors for a patient’s OS
were cell differentiation (P = 0.025), pT stage (P = 0.003),
pN stage (P < 0.001), and FAM3C expression (P < 0.001)
(Table 2). In the multivariate Cox analyses, cell differ-
entiation (P = 0.043), pT stage (P = 0.045), pN stage
(P < 0.001), and FAM3C expression (P = 0.022) were
shown to be the independent prognostic predictors
for OS (Table 2). Further, in a stratified survival analysis
according to the TNM stage, FAM3C expression could
differentiate the prognosis of patients with TNM stage I-II
(P = 0.011; Fig. 2b).
Discussion
EMT plays pivotal roles during tumor progression
through endowing cells with migratory and invasive
properties, inducing stem cell properties, and preventing
apoptosis and senescence [15]. FAM3C was regarded as
a key regulator of EMT and metastatic progression in
both human and mouse models [10, 11]. In the current
study, we found that 70.0 % of ESCC patients showed
elevated FAM3C expression in their tumor tissues com-
pared with the normal counterparts. Our results also
showed that the expression of FAM3C was associated
with the expression of E-cadherin and vimentin, which
are the vital factors in the process of EMT. Further, the
genetic-clinicopathologic correlation analysis indicated
that patients with high expression of FAM3C in tumor-
ous specimens tended to have more advanced pT stage,
pN stage and a higher TNM stage. These findings sug-
gest that FAM3C may initiate EMT process, and thus
contributing to ESCC metastasis and progression.
Consistent with our results, recent investigations dem-
onstrated that overexpression of FAM3C correlated
with EMT and metastasis in breast cancer and colon
cancer [10, 13].
EMT, a switch of polarized epithelial cells to a highly
motile mesenchymal phenotype, is a developmental event
recognized as a central process during cancer progression
and metastasis [16, 17]. TGF-β has been implicated as a
“master switch” in EMT process, which regulates expres-
sion of numerous downstream transcription factors in-
volved in EMT without or with the collaboration of other
signaling effectors [18, 19]. Several works revealed that
TGF-β-induced EMT was mediated through the induction




Cases FAM3C mRNA expression P value
low level (%) high level (%)
Age (years old) 0.204
≤59 49 28 (57.1 %) 21 (42.9 %)
>59 58 26 (44.8 %) 32 (55.2 %)
Gender 0.954
Male 79 40 (50.6 %) 39 (49.4 %)
Female 28 14 (50.0 %) 14 (50.0 %)
Location 0.811
Upper 12 5 (41.7 %) 7 (58.3 %)
Middle 60 31 (51.7 %) 29 (48.3 %)
Lower 35 18 (51.4 %) 17 (48.6 %)
Differentiation 0.843
Grade 1 20 9 (45.0 %) 11 (55.0 %)
Grade 2 57 29 (50.9 %) 28 (49.1 %)
Grade 3 30 16 (53.3 %) 14 (46.7 %)
pT stage 0.014
T1-2 25 18 (72.0 %) 7 (28.0 %)
T3-4 82 36 (43.9 %) 46 (56.1 %)
pN stage 0.026
N0 56 34 (60.7 %) 22 (39.3 %)
N1-3 51 20 (39.2 %) 31 (60.8 %)
TNM stage 0.003
I-II 60 38 (63.3 %) 22 (36.7 %)
III 47 16 (34.0 %) 31 (66.0 %)
Statistical significance (P < 0.05) is shown in bold
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of FAM3C in murine epithelial cells [11, 20, 21]. Hetero-
geneous nuclear ribonucleoprotein (hnRNP E1) repressed
FAM3C translation by binding to a TGF-β-activated trans-
lation (BAT) element in the 3′UTR of FAM3C. The
activation of TGF-β induced phosphorylation at Ser43 of
hnRNP E1 by protein kinaseBβ/Akt2, which resulted in its
release from the BAT element and thus reversed the
translation inhibition of FAM3C [11, 20, 21]. Recently, a
similar translational regulation pattern of FAM3C was
observed in human lung cancer cell line A549 [22].
These data indicated that FAM3C was regulated by
post-translational modification during EMT. Besides,
our initial RNA-Seq profiling data and subsequent qRT-
PCR analysis demonstrated that the expression of FAM3C
was upregulated at RNA level in ESCCs. FAM3C was
located on chromosome 7q31. Amplification of 7q is one
of the most frequent allelic imbalances in ESCC detected
by comparative genomic hybridization (CGH) [23, 24],
suggesting the existence of one or more ESCC-related
oncogenes within this region. Accordingly, it raises the
possibility that the gains in 7q may contribute to the
overexpression of FAM3C mRNA in ESCC. Based on
these findings, we speculate that the expression of
FAM3C may be regulated via multiple mechanisms
including post-transltional modification, DNA copy
number change, hypermethylation, histone deacetyla-
tion, miRNA regulation, etc. Further elucidation for the
precise mechanism underlying the regulation of FAM3C
expression in ESCC is required.
Early research demonstrated that FAM3C alone was suf-
ficient to induce EMT, tumor growth and metastasis in
murine mammary epithelium cell EpH4, independently of
TGF-β activation [10]. However, a recent research revealed
that exogenous FAM3C strictly required co-operation with
oncogenic Ras to cause TGF-β-independent EMT and
tumor progression in human hepatocytes [25]. These
results suggest that the underlying mechanisms of FAM3C
involved in EMT may vary depending on the epithelial cell
type and tissue context. Moreover, the result that endogen-
ous, secreted FAM3C-induced EMT could be partially
suppressed by a neutralizing antibody against FAM3C in
EpRas cells [10], implies that FAM3C may induce multiple
autocrine growth factors and chemokines loops to cause
TGF-β-independent EMT. Interestingly, activation of auto-
crine PDGF/PDGF-R signaling was observed in both
FAM3C-induced murine mammary epithelial EMT and
RAS/FAM3C-induced hepatocellular EMT [10, 25]. This
raises the question of whether FAM3C acts on EMT-
Fig. 2 Kaplan-Meier analysis of OS for FAM3C expression. a Kaplan-Meier analysis of OS for FAM3C expression in 107 cases of ESCC patients. b Stratified
survival analysis according to the TNM stage
Table 2 Cox proportional hazard regression analyses for overall survival
Clinical features Univariate analysis Multivariate analysis
HR (95 % CI) P value HR (95 % CI) P value
Age 1.321 (0.747–2.337) 0.338 – –
Gender 0.613 (0.297–1.265) 0.186 – –
Location 1.012 (0.647–1.583) 0.958 – –
Differentiation 1.574 (1.014–2.443) 0.025 1.659 (1.016–2.708) 0.043
pT stage 5.922 (1.838–19.089) 0.003 3.463 (1.029–11.661) 0.045
pN stage 5.470 (2.864–10.447) <0.001 3.789 (1.937–7.409) <0.001
FAM3C expression 2.941 (1.606–5.389) <0.001 2.067 (1.109–3.854) 0.022
HR Hazard ratio, CI Confidence interval
Statistical significance (P < 0.05) is shown in bold
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associated autocrine loops or the specific FAM3C re-
ceptors. Nevertheless, until now, the precise FAM3C-
dependent signal transduction pathways or receptors
involved in EMT are not completely understood.
More importantly, our data demonstrated that ele-
vated expression of FAM3C was significantly associ-
ated with poor OS of ESCC patients. Patients with
high FAM3C expression displayed a remarkably lower
rate of 7-year OS than those with low FAM3C expres-
sion. Moreover, with the stratified survival analysis
according to the TNM stage, we found that high ex-
pression FAM3C could identify the subgroup of
patients with poor outcomes among the early clinical
stage (TNM stage I-II) cases, but not the advanced
clinical stage ( TNM stage III). Metastasis is regarded
as a multistep process characterized by dissociation of
tumor cells from adjacent normal cells, penetration
into the underlying interstitial matrix, intravasation,
survival in the circulation, extravasation at a distant
organ site and growth of metastatic cells in the distant
organ [26]. Accumulating evidence indicates that EMT
is involved in the early steps of metastasis [27, 28].
Overexpression of FAM3C may induce the incipient
ESCC cells to undergo EMT and subsequently acquire
invasive and migratory abilities, which leads to the
poor prognosis in early clinical stage. The overall sur-
vival rate of patients with advanced clinical stage
remains dismal, which is attributed to metastatic re-
lapse after resection of the primary tumor. According
to the metastasis model, only the cancer cells that
adopt various strategies can be survive and eventually
outgrow in the target organ. In addition, systemic sig-
nals, which act directly or indirectly on the micro-
environment in which metastases arise, have impacts
on latter steps in the metastatic cascade [29, 30].
Hence, the prognostic significance of FAM3C did not
retain in advanced clinical stage. Together, data from
the current study imply that combining FAM3C
mRNA expression and clinicopathological variables
may predict outcomes of patients with early patho-
logical stage more accurately. Accordingly, postopera-
tive adjuvant therapy or careful follow-up may be
recommended for this subgroup of patients to improve
the postoperative outcomes. However, further studies
are required with larger sample sizes to validate these
findings.
Conclusions
In the present study, we, for the first time, reported
that FAM3C expression was upregulated in ESCC,
which was associated with aggressive tumor behavior,
metastasis, and poor clinical outcome. Therefore,
FAM3C may be a valuable biomarker for the prediction
of ESCC prognosis.
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